| Bioactivity | LSD1-IN-35 (Compound Z-1) is a selective LSD1 Inhibitor (IC50: 108 nM). LSD1-IN-35 inhibits the demethylation on H3K4me1/2. LSD1-IN-35 is an immunomodulator. LSD1-IN-35 promotes response of gastric cancer cells to T-cell killing effect by decreasing PD-L1 expression and further attenuates the PD-1/PD-L1 interaction[1]. |
| CAS | 2992690-04-5 |
| Formula | C25H26N4O2S |
| Molar Mass | 446.56 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Bo Wang, et al. Discovery of 2-Aryl-4-aminoquinazolin-Based LSD1 Inhibitors to Activate Immune Response in Gastric Cancer. Med. Chem. 2024, 67, 18, 16165-16184. |
LSD1-IN-35
CAS: 2992690-04-5 F: C25H26N4O2S W: 446.56
LSD1-IN-35 (Compound Z-1) is a selective LSD1 Inhibitor (IC50: 108 nM). LSD1-IN-35 inhibits the demethylation on H3K4me1
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.